A detailed history of Korea Investment Corp transactions in Legend Biotech Corp stock. As of the latest transaction made, Korea Investment Corp holds 42,590 shares of LEGN stock, worth $1.74 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
42,590
Previous 12,390 243.74%
Holding current value
$1.74 Million
Previous $548,000 278.65%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$43.55 - $59.88 $1.32 Million - $1.81 Million
30,200 Added 243.74%
42,590 $2.08 Million
Q2 2024

Aug 13, 2024

SELL
$39.5 - $57.22 $1.37 Million - $1.98 Million
-34,600 Reduced 73.63%
12,390 $548,000
Q1 2024

May 14, 2024

SELL
$55.06 - $69.99 $214,734 - $272,961
-3,900 Reduced 7.66%
46,990 $2.64 Million
Q4 2023

Feb 13, 2024

BUY
$57.25 - $69.74 $171,750 - $209,219
3,000 Added 6.26%
50,890 $3.06 Million
Q3 2023

Nov 13, 2023

BUY
$63.16 - $76.5 $360,012 - $436,050
5,700 Added 13.51%
47,890 $3.22 Million
Q2 2023

Aug 11, 2023

BUY
$46.28 - $75.01 $624,780 - $1.01 Million
13,500 Added 47.05%
42,190 $2.91 Million
Q1 2023

May 12, 2023

SELL
$43.42 - $57.37 $130,260 - $172,110
-3,000 Reduced 9.47%
28,690 $1.38 Million
Q4 2022

Feb 13, 2023

BUY
$38.8 - $55.46 $193,612 - $276,745
4,990 Added 18.69%
31,690 $1.58 Million
Q3 2022

Nov 10, 2022

SELL
$38.15 - $57.1 $377,685 - $565,290
-9,900 Reduced 27.05%
26,700 $1.09 Million
Q2 2022

Aug 12, 2022

SELL
$33.54 - $55.0 $517,824 - $849,145
-15,439 Reduced 29.67%
36,600 $2.01 Million
Q1 2022

May 13, 2022

BUY
$31.02 - $48.18 $854,259 - $1.33 Million
27,539 Added 112.4%
52,039 $1.89 Million
Q4 2021

Feb 09, 2022

BUY
$41.14 - $56.98 $1.01 Million - $1.4 Million
24,500 New
24,500 $1.14 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.85B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Korea Investment Corp Portfolio

Follow Korea Investment Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Korea Investment Corp, based on Form 13F filings with the SEC.

News

Stay updated on Korea Investment Corp with notifications on news.